A definitive method is definitive only within its validated scope.
The assay targeted alprazolam, bromazepam, clonazepam, diazepam and flunitrazepam in urine. It reported a quantitation limit of 6 ng/mL and was applied to forty-eight forensic samples from people suspected of drug use. Positivity was high in that selected set.
The selected-case positivity percentage is not a population prevalence estimate. Parent drugs, metabolites and designer compounds outside the panel remain separate analytical questions. Validation in urine does not automatically validate another matrix.
Request the complete analyte list and reporting limits rather than relying on the phrase mass spectrometry. A negative target result cannot exclude every benzodiazepine exposure. A positive urine identification cannot independently establish when a dose was taken, its amount or functional impairment at an earlier event.
Source: PMC12430268, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Carbamazepine–Alprazolam Interaction Modeling Included Autoinduction.